Protein Blends (Soy, Whey and Casein) for Muscle Synthesis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Soy protein is a high quality, plant-based protein that is comparable to milk, meat and eggs. Soy protein has a digestion rate (intermediate) compared to whey (fast) and casein (slow). This intermediate rate may allow soy protein to have an extended window of muscle protein synthesis that has not been monitored in previous studies. While most of the sports nutrition "recovery" products are dairy-based protein blends (high in branched-chain amino acids), soy protein offers additional benefits that can make an important contribution to these types of sports nutrition products. Soy protein contains approximately 300% more arginine and 30% more glutamine compared to whey protein and these two amino acids may bring additional benefits (immunity and hydration, respectively) to athletes. A "blend" of high-quality proteins (soy and dairy) may be the optimal sports nutrition product for athletes to consume following training.
| Condition | Intervention |
|---|---|
|
Muscle Synthesis |
Other: Protein Blend |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Basic Science |
| Official Title: | A Randomized, Controlled Double Blind Acute Study: Effects of Protein Blends on Muscle Protein Synthesis and Breakdown |
- Muscle Protein Synthesis or Fractional synthesis rate (FSR) [ Time Frame: baseline, 3 hours, 5 hours ] [ Designated as safety issue: No ]The fractional synthesis rate (FSR) of mixed muscle proteins will be calculated from the incorporation rate of L-[ring-13C6]Phenylalanine into the mixed muscle proteins, and the free-tissue phenylalanine enrichment.
- oxidative and inflammatory markers [ Time Frame: baseline, 3 hours, 5 hours ] [ Designated as safety issue: No ]Proteins will be assessed that are markers of oxidative damage and inflammation (NFkB, IL-1, IL-6) and proteolysis (MuRF, MAFBx).
- Phosphorylation of protein in muscle protein signaling pathways [ Time Frame: baseline, 3 hours, 5 hours ] [ Designated as safety issue: No ]Phosphorylation of mTOR, 4E-BP1, S6K1, S6, and eEF2 will be measured using Western blot techniques as previously described.
| Estimated Enrollment: | 20 |
| Study Start Date: | January 2011 |
| Estimated Study Completion Date: | March 2013 |
| Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Whey Protein Isolate |
Other: Protein Blend
Single intake of approximately 20 grams of total protein
|
| Experimental: Protein Blend (soy, whey and casein) |
Other: Protein Blend
Single intake of approximately 20 grams of total protein
|
Eligibility| Ages Eligible for Study: | 18 Years to 35 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion:
- Age 18-35 yrs
- Stable body weight for at least 1 year
Exclusion criteria will be:
- Exercise training (>2 weekly sessions of moderate to high intensity aerobic or resistance exercise)
- Significant heart, liver, kidney, blood, or respiratory disease
- Peripheral vascular disease
- Diabetes mellitus or other untreated endocrine disease
- Active cancer (all groups) and history of cancer (groups potentially randomizable to rapamycin)
- Acute infectious disease or history of chronic infections (e.g. TB, hepatitis, HIV, herpes)
- Recent (within 6 months) treatment with anabolic steroids, or corticosteroids.
- Alcohol or drug abuse
- Tobacco use (smoking or chewing)
- Malnutrition (BMI < 20 kg/m2, hypoalbuminemia, and/or hypotransferrinemia)
- Obesity (BMI > 30 kg/m2)
- Low hemoglobin levels (below normal values)
- Food allergies
- Taking dietary supplements such as green tea, etc.
- Currently on a high-soy diet (consuming >2 servings of soy per day)
Contacts and Locations| United States, Texas | |
| UTMB General Clinical Research Center, located in the John Sealy Hospital | |
| Galveston, Texas, United States, 77555 | |
| Principal Investigator: | Ratna Mukherjea, PhD | Solae, LLC |
| Principal Investigator: | Mark B Cope, PhD | Solae, LLC |
| Principal Investigator: | Blake B Rasmussen, PhD | UTMB |
More Information
No publications provided by Solae, LLC
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Solae, LLC |
| ClinicalTrials.gov Identifier: | NCT01358305 History of Changes |
| Other Study ID Numbers: | CRC-D-176 |
| Study First Received: | May 19, 2011 |
| Last Updated: | February 14, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Solae, LLC:
|
muscle synthesis mTOR antioxidant |
inflammatory markers soy protein whey casein |
Additional relevant MeSH terms:
|
Caseins Chelating Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013